WhiteSwell has revealed positive six-month outcomes for patients with acute decompensated heart failure (ADHF), treated with its eLym System, as part of the ongoing DELTA-HF trial.
The DELTA-HF trial is a non-randomised early feasibility study assessing the eLym System’s safety and performance.
The eLym System is a minimally invasive catheter-based system. It is designed to allow the removal of excess fluid from tissues and organs (interstitial fluid) in patients with ADHF.
